From Pharmaceutical Technology:
Quality Chemical's new facility began to produce the triple therapy ARV and a first line antimalarial therapy in January 2008...the plant will produce the triple therapy combination Triomune (containing lamivudine, stavudine and nevirapine) and also the antimalarial therapy Lumartem (containing artemisinin and lumefantrin)...The plant will produce two million tablets per day per shift and 600 million tablets per year. The immediate future production target is 1.2 billion tablets when the plant is fully operational (expansion may be required). The facility will employ 500 personnel including 200 scientists for research and development...[continue reading]
0 comments:
Post a Comment